Cimzia®

Understanding Cimzia® 

Cimzia® (certolizumab pegol) is a biologic medication designed to reduce inflammation by targeting and inhibiting tumor necrosis factor-alpha (TNF-α), a protein that plays a central role in inflammatory processes. It is utilized in the treatment of various autoimmune and inflammatory conditions.

How Cimzia® Works:

• TNF-α Inhibition: Cimzia® binds to TNF-α, blocking its interaction with TNF receptors, thereby reducing inflammation and altering the immune response associated with various autoimmune conditions.

• Administration: Administered via subcutaneous injection. The dosing regimen varies based on the specific condition being treated.

FDA Approval:

• Cimzia® received its initial FDA approval on April 22, 2008, for the treatment of Crohn’s disease. Subsequent approvals expanded its indications to include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and non-radiographic axial spondyloarthritis.

For more information, please visit the Cimzia® patient website and consult your healthcare provider to determine if Cimzia® is the right treatment option for you.